12Oct 2023
DELIVER Study Reveals Significant Impact of COVID-19 on Heart Failure Patients, Affirms Dapagliflozin's Treatment Benefits

DELIVER Study Reveals Significant Impact of COVID-19 on Heart Failure Patients, Affirms Dapagliflozin's Treatment Benefits

The DELIVER study investigated the impact of COVID-19 on patients with heart failure. Participants with heart failure and reduced ejection fraction were randomized to receive dapagliflozin or a placebo. Of the 6263 participants, 9.4% developed COVID-19, with 52% requiring hospitalization. COVID-19 was associated with a significantly increased risk of death, particularly in the first 3 months after diagnosis. Even after censoring for COVID-19 events, dapagliflozin showed benefits in reducing cardiovascular events. This extensive study highlights the substantial impact of COVID-19 on heart failure patients and the potential benefits of dapagliflozin treatment.

  • #cardiology

Like

Save

Share